RxDoctor Payments Data

Jacob Jipp, MD

Urology · Clive, IANPI 1164886644

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,002 of the $2,987 with a category attached, or 67.0%. 25 manufacturers reported payments, led by Teleflex LLC at 38.2% of the total. Reporting peaked in 2021 at $1,296 and has fallen 84.0% since, to $208 in 2025.

$2,987in general payments, 2019–2025

Across 69 payments — averaging $43.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$1K
  • Medtronic$333
  • Boston Scientific$248
  • Dornier Medtech America, Inc$195
  • AbbVie$144
  • Myriad Genetic Laboratories, Inc.$132
  • plus $794 from 19 others

What the payments were for

  • Travel & lodging$92031%
  • Food & beverage$2,00267%
  • Education$652%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,987 in reported general payments places this provider in the 60th percentile of 114 urology providers in Iowa.

See all urology providers in Iowa

Medicare billing

Part B allowed, 2024
$102,764
Medicare patients
337
Services billed
1,090

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix16$39,767
Abiraterone Acetate17$12,904
MyrbetriqMirabegron20$12,576
Tamsulosin Hcl273$2,694
Potassium Citrate ErPotassium Citrate15$2,004
Solifenacin Succinate44$1,978
Trospium Chloride ErTrospium Chloride12$1,823
Oxybutynin Chloride ErOxybutynin Chloride106$1,508
Trospium Chloride25$1,034
Finasteride67$661
Cephalexin46$195
Oxycodone Hcl42$105
Ciprofloxacin Hcl29$101
Prednisone34$95
Tramadol Hcl37$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$94$12,57620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 114 urology providers in Iowa.

Other urology in Clive

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →